PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Phase 1/2 Terminated 17 enrolled AIDS Malignancy Consortium National Cancer Institute (NCI) · collab PTC Therapeutics · collab The Emmes Company, LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.

Timeline

Start: 2008-09
Primary completion: 2010-11
Completion: 2010-12

Publications

Background Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE; AIDS Malignancy Consortium (AMC)-059 Study Team. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 1;72(1):52-7. doi: 10.1097/QAI.0000000000000918.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EMVODODSTAT	Small molecule	40 mg	Oral
Subject	EMVODODSTAT	Small molecule	80 mg	Oral
Subject	EMVODODSTAT	Small molecule	100 mg	Oral

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Summary

Timeline

Publications

Drugs

Indications